JCB logo
BioLegend: Antibody Reagents
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 21 August 2000. doi:10.1083/jcb.150.4.873
This Article
Right arrow Full Text
Right arrow PDF (Full Text)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, A.
Right arrow Articles by Nakanishi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, A.
Right arrow Articles by Nakanishi, M.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH
*Genetics Home Reference
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0021-9525/2000/8/873/ $5.00
The Journal of Cell Biology, Volume 150, Number 4, August 21, 2000 873-880


Report

Cyclin E As a Coactivator of the Androgen Receptor

Ayako Yamamotoa, Yoshihiro Hashimotob,c, Kenjiro Kohric, Etsuro Ogatae, Shige-aki Katoa,f, Kyoji Ikedab, and Makoto Nakanishib,d
a Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo 113, Japan
b Department of Geriatric Research, National Institute for Longevity Sciences, Obu, Aichi 474-8522, Japan
c Department of Urology, Nagoya City University Medical School, Nagoya 467-8601, Japan
d Department of Biochemistry, Nagoya City University Medical School, Nagoya 467-8601, Japan
e Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 170-8455, Japan
f CREST, Japan Science and Technology Corporation, Saitama 332, Japan

Correspondence to: Makoto Nakanishi, Department of Biochemistry, Nagoya City University Medical School, Kawasumi 1, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Tel:+81-52-853-8145 Fax:+81-52-842-3955 E-mail:mkt-naka{at}med.nagoya-cu.ac.jp.

Androgens play an important role in the growth of prostate cancer, but the molecular mechanism that underlies development of resistance to antiandrogen therapy remains unknown. Cyclin E has now been shown to increase the transactivation activity of the human androgen receptor (AR) in the presence of its ligand dihydrotestosterone. The enhancement of AR activity by cyclin E was resistant to inhibition by the antiandrogen 5-hydroxyflutamide. Cyclin E was shown to bind directly to the COOH terminus portion of the AB domain of the AR, and to enhance its AF-1 transactivation function. These results suggest that cyclin E functions as a coactivator of the AR, and that aberrant expression of cyclin E in tumors may contribute to persistent activation of AR function, even during androgen ablation therapy.

Key Words: cyclin E, androgen receptor, prostate cancer, coactivator, cell cycle


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents